Last reviewed · How we verify
Rescue Medication: Loratadine tablets
Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.
Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria.
At a glance
| Generic name | Rescue Medication: Loratadine tablets |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | H1-receptor antagonist (second-generation/non-sedating antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Loratadine competitively binds to peripheral H1 histamine receptors, preventing histamine from triggering allergic symptoms such as itching, sneezing, and urticaria. As a non-sedating antihistamine, it has minimal blood-brain barrier penetration due to its molecular structure and active efflux by P-glycoprotein, resulting in reduced central effects compared to first-generation antihistamines.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Chronic urticaria
Common side effects
- Headache
- Somnolence
- Fatigue
- Dry mouth
- Nervousness
Key clinical trials
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (PHASE3)
- Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rescue Medication: Loratadine tablets CI brief — competitive landscape report
- Rescue Medication: Loratadine tablets updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI